Gastrooesophageal cancer develops at the point where the food pipe meets the stomach, forming a distinct type of cancer that behaves differently from cancers of either organ alone. Understanding the treatment options, both established and experimental, can help patients and their families navigate the challenging journey ahead.

How Treatment Approaches Target This Cancer

When someone receives a diagnosis of gastrooesophageal cancer, also called gastro-oesophageal junction (GOJ) cancer, the treatment plan aims to remove or control the tumor, ease symptoms, and maintain the best possible quality of life. The specific approach depends on how far the cancer has spread, where exactly the tumor is located, and the person’s overall health and fitness level. Because this cancer sits at the junction between the food pipe and stomach, treatment decisions must consider the unique anatomy of this area and how surgery or other therapies will affect a person’s ability to eat and digest food^[3].

Medical teams use a combination of therapies rather than relying on just one method. For cancers caught early before they have spread beyond the junction area, doctors focus on curative treatment designed to eliminate the disease completely. This usually involves surgery, often combined with chemotherapy or radiation therapy. When the cancer has already spread to distant parts of the body, treatment shifts to a palliative approach, meaning the goal becomes controlling the cancer’s growth, relieving symptoms like difficulty swallowing, and helping people live as comfortably as possible for as long as possible^[2][11].

The treatment journey typically requires a team of specialists working together. This multidisciplinary team includes surgeons who specialize in removing gastrointestinal tumors, medical oncologists who prescribe chemotherapy and newer drug treatments, radiation oncologists who deliver targeted radiation, nutritionists who help maintain proper nutrition during treatment, and nurses who coordinate care. Because gastroesophageal cancer is relatively uncommon compared to other cancers, seeking care at a center with experience treating this specific type can make a significant difference in outcomes^[4][6].

Standard Treatment Methods

The foundation of treatment for gastrooesophageal junction cancer depends on the disease stage and the exact location of the tumor. Doctors classify GOJ cancers into three types based on where the center of the tumor sits. Type 1 cancers have their center between 1 and 5 centimeters above the junction in the lower esophagus. Type 2 cancers center directly at the junction itself, within 1 centimeter above or 2 centimeters below it. Type 3 cancers center between 2 and 5 centimeters below the junction in the upper stomach. The type influences which surgical approach works best^[3].

Surgery as Primary Treatment

For patients whose cancer has not spread to distant organs and who are healthy enough to tolerate a major operation, surgery offers the best chance for cure. The surgeon removes the tumor along with a margin of healthy tissue around it to ensure no cancer cells remain at the edges. They also remove nearby lymph nodes, which are small bean-shaped structures that filter lymph fluid and can harbor cancer cells. For Type 1 GOJ cancers, surgeons typically perform an oesophagectomy, removing about two-thirds of the esophagus and possibly the top portion of the stomach. For Type 2 and 3 cancers, the operation might involve removing part of both the esophagus and stomach, or in some cases, the entire stomach along with the lower esophagus^[11].

These operations are complex and require several hours in the operating room. Surgeons may perform them through traditional open incisions or using minimally invasive techniques with several small incisions and special instruments. Patients typically remain in the hospital for 7 to 10 days after surgery and need 4 to 6 weeks to recover at home. Because the stomach and esophagus play crucial roles in digestion, removing part or all of these organs permanently changes how the body processes food. Many patients need to eat smaller, more frequent meals and may experience difficulties that require ongoing nutritional support^[17][18].

For very early cancers that have not grown deeply into the wall of the esophagus or stomach, doctors might perform an endoscopic resection instead of major surgery. During this procedure, the doctor passes a long, flexible tube with a camera and cutting tools down the throat to reach the tumor. They remove the cancerous tissue through the tube without making any external incisions. This approach works only for small, superficial tumors but allows people to recover much faster than after traditional surgery^[11].

Chemotherapy and Radiation Therapy

Most patients with gastrooesophageal cancer that has grown beyond the earliest stages receive chemotherapy in addition to surgery. Chemotherapy uses powerful drugs that travel through the bloodstream to kill cancer cells throughout the body. Doctors typically give chemotherapy both before and after surgery, an approach called perioperative chemotherapy. The chemotherapy given before surgery aims to shrink the tumor, making it easier to remove completely and killing any cancer cells that might have already spread microscopically. The chemotherapy given after surgery targets any remaining cancer cells to reduce the risk of the cancer returning^[11][13].

Common chemotherapy drugs used for gastroesophageal cancer include combinations of agents that work together more effectively than single drugs. These medications can cause side effects such as nausea, vomiting, fatigue, loss of appetite, mouth sores, and temporary lowering of blood cell counts that increases infection risk. Modern supportive medications have improved doctors’ ability to prevent or reduce many of these side effects, making chemotherapy more tolerable than in the past^[16].

Radiation therapy uses high-energy beams, similar to X-rays but much stronger, to damage cancer cells’ DNA and prevent them from dividing. For gastroesophageal junction cancer, doctors often combine radiation with chemotherapy in a treatment approach called chemoradiotherapy. The chemotherapy makes cancer cells more sensitive to radiation damage. Patients typically receive chemoradiotherapy for about six weeks before surgery. Some patients who cannot have surgery because of other health problems or because the cancer has spread too far may receive chemoradiotherapy as their main treatment^[11][13].

Radiation therapy for this area requires careful planning to target the cancer while minimizing exposure to nearby organs such as the heart, lungs, and spinal cord. Patients receive treatments five days per week, with each session lasting just a few minutes. The treatment itself is painless, but side effects accumulate over the weeks of therapy and can include fatigue, skin irritation in the treatment area, difficulty swallowing, and inflammation of the esophagus that makes eating uncomfortable^[10].

Newer Approved Therapies

In recent years, the treatment landscape for gastroesophageal cancers has expanded beyond traditional chemotherapy and radiation. Immunotherapy drugs help the body’s own immune system recognize and attack cancer cells. Some gastroesophageal junction cancers produce high levels of a protein called PD-L1 that acts like a shield, preventing immune cells from attacking the tumor. Immunotherapy drugs called checkpoint inhibitors block this protective mechanism, allowing the immune system to fight the cancer. Doctors test tumor samples to determine whether a patient’s cancer is likely to respond to immunotherapy based on PD-L1 levels and other markers^[14][15].

Targeted therapy drugs attack specific molecules that cancer cells need to grow and survive. For gastroesophageal cancers that produce too much of a protein called HER2, drugs that target this protein can slow cancer growth. Trastuzumab is one such drug approved for HER2-positive gastroesophageal cancers. Doctors test tumor tissue for HER2 overexpression to identify which patients will benefit from these targeted therapies. When appropriate, these drugs are combined with chemotherapy to improve treatment effectiveness^[14].

Treatment recommendations follow guidelines developed by professional medical societies based on clinical trial results. These guidelines specify which treatments should be used for different stages and types of gastroesophageal cancer. However, every patient’s situation is unique, and doctors may adjust standard recommendations based on individual circumstances such as other health conditions, age, personal preferences, and how well someone tolerates initial treatments^[14].

Experimental Treatments in Clinical Trials

While standard treatments have improved outcomes for many patients with gastroesophageal cancer, researchers continue searching for more effective therapies through clinical trials. These research studies test new drugs, new combinations of existing drugs, and entirely new treatment approaches. Participating in a clinical trial gives patients access to cutting-edge treatments before they become widely available. Clinical trials follow strict safety protocols and are carefully monitored by medical experts and regulatory authorities^[12][14].

Phases of Clinical Trials

Phase I trials focus primarily on safety. Researchers test a new drug or treatment in a small group of patients to determine the appropriate dose, identify side effects, and understand how the body processes the treatment. Phase I trials for cancer typically include patients whose cancer has not responded to standard treatments. While the main goal is safety rather than effectiveness, some patients do experience tumor shrinkage or disease stabilization in Phase I studies^[12].

Phase II trials test whether a treatment works against a specific type of cancer. These studies include more patients than Phase I trials and continue to monitor safety while focusing on measuring how many patients respond to the treatment. Researchers look at outcomes such as tumor shrinkage, how long patients live without their cancer worsening, and overall survival. Phase II results help determine whether a treatment is promising enough to move forward to larger studies^[12].

Phase III trials compare a new treatment directly against the current standard treatment in large groups of patients. These randomized studies assign patients by chance to receive either the experimental treatment or the standard treatment. Phase III trials provide the strongest evidence about whether a new approach is better than what doctors currently use. If a Phase III trial shows that a new treatment is more effective or causes fewer side effects, regulatory agencies may approve it for general use^[12].

Phase IV trials continue to study a treatment after it has been approved and is in widespread use. These studies collect information about long-term side effects, how the treatment works in diverse patient populations, and optimal ways to use it in combination with other therapies^[12].

Promising New Approaches

Several innovative treatment strategies are being tested specifically for gastroesophageal junction and related cancers. Researchers are exploring new immunotherapy drugs and combinations that might work for patients whose tumors do not respond to currently available immunotherapy. Some studies test combinations of different checkpoint inhibitors that block multiple immune system brakes simultaneously. Other trials combine immunotherapy with targeted therapy drugs or with chemotherapy to see if the combination produces better results than either approach alone^[12][14].

Personalized medicine approaches analyze the unique genetic makeup of each patient’s tumor to identify specific mutations or abnormalities that could be targeted with drugs. Advances in genetic testing technology now allow doctors to sequence tumor DNA and look for dozens of different genetic changes. When testing identifies a targetable mutation, patients may be eligible for clinical trials of drugs designed to attack that specific genetic abnormality. This approach moves away from treating all gastroesophageal cancers the same way and instead tailors treatment to each tumor’s molecular characteristics^[14].

Some clinical trials are testing whether immunotherapy given before or after surgery can help prevent cancer from returning. The CheckMate-577 trial, for example, showed that the immunotherapy drug nivolumab given after surgery and chemoradiotherapy helped patients with esophageal or gastroesophageal junction cancer live longer without their cancer coming back. This led to approval of nivolumab for this specific use. Ongoing studies are testing whether immunotherapy can be helpful even earlier in the treatment process, such as before surgery, or in combination with chemotherapy^[15].

Researchers are also investigating new ways to deliver existing treatments more effectively. Studies are testing different sequences of chemotherapy, radiation, and surgery to determine the optimal timing of each treatment. Other trials examine whether shorter courses of treatment might be just as effective as longer ones while causing fewer side effects and allowing patients to return to normal activities sooner^[12].

Clinical trials for gastroesophageal cancer are conducted at major cancer centers in the United States, Europe, and other regions around the world. Some trials are available only at a few specialized centers, while others enroll patients at many different locations. Eligibility criteria vary by study but typically include requirements about the stage of cancer, whether it has been treated before, and the patient’s ability to perform normal daily activities. Clinical trial teams include doctors, nurses, and research coordinators who monitor participants closely throughout the study^[12].

Most common treatment methods

• Surgery
  • Oesophagectomy removes about two-thirds of the esophagus along with nearby lymph nodes and sometimes the top of the stomach
  • Extended total gastrectomy removes the stomach, lower esophagus, and surrounding lymph nodes
  • Endoscopic resection removes very early-stage cancers through a tube passed down the throat without external incisions
  • Operations can be performed through open incisions or minimally invasive approaches
• Chemotherapy
  • Uses drugs that travel through the bloodstream to kill cancer cells throughout the body
  • Perioperative chemotherapy is given both before and after surgery
  • Common regimens combine multiple drugs that work together more effectively than single agents
  • May be the main treatment when surgery is not possible
• Radiation Therapy
  • Uses high-energy beams to damage cancer cell DNA
  • Often combined with chemotherapy as chemoradiotherapy before surgery
  • Treatment typically lasts about six weeks with daily sessions
  • Can be used to relieve symptoms such as difficulty swallowing in advanced disease
• Immunotherapy
  • Checkpoint inhibitor drugs help the immune system recognize and attack cancer cells
  • Used for cancers with high PD-L1 expression or certain other markers
  • Nivolumab is approved after surgery and chemoradiotherapy to reduce recurrence risk
  • Being tested in combination with chemotherapy and in earlier stages of treatment
• Targeted Therapy
  • Drugs attack specific molecules that cancer cells need to grow
  • Trastuzumab targets HER2 protein in HER2-positive tumors
  • Requires testing of tumor tissue to identify which patients will benefit
  • Usually combined with chemotherapy

Managing Eating and Nutrition During Treatment

One of the most challenging aspects of living with gastroesophageal cancer is maintaining adequate nutrition. The tumor itself can make swallowing difficult and painful, a symptom called dysphagia. As the cancer grows, it can narrow the opening at the gastroesophageal junction, making it harder for food to pass from the esophagus into the stomach. This often leads to weight loss even before treatment begins^[1][4].

Treatment further complicates eating. Chemotherapy can cause nausea, vomiting, loss of appetite, and changes in taste that make food unappealing. Radiation to the chest area inflames the esophagus, making swallowing painful. Surgery that removes part of the esophagus or stomach permanently changes the digestive system’s anatomy and function. After surgery, the remaining stomach or the section of intestine used to replace the stomach is smaller, so people feel full after eating just a small amount of food^[19][21].

Working with a registered dietitian who specializes in cancer nutrition is essential. These professionals can recommend strategies to maximize calorie and protein intake despite eating difficulties. For people with swallowing problems, a soft diet that includes foods like scrambled eggs, mashed potatoes, smoothies, soups, yogurt, and pudding can be easier to manage than regular solid foods. Adding extra calories through butter, cream, cheese, and nutritional supplement drinks helps prevent weight loss. Some patients benefit from eating six to eight small meals throughout the day rather than three large meals^[19][24][25].

When eating by mouth does not provide enough nutrition, doctors may recommend tube feeding. A feeding tube can be inserted through the nose down into the stomach for short-term use. For longer-term feeding support, a tube can be placed directly through the abdominal wall into the small intestine (J-tube) or stomach (G-tube) during a minor surgical procedure. Liquid nutrition formulas that contain all necessary calories, protein, vitamins, and minerals flow through the tube. Many patients learn to manage tube feeding at home, giving themselves nutrition overnight or during the day while still eating some foods by mouth when possible. The tube can be removed later if oral eating improves^[19][24].

After recovering from surgery, most people eventually adjust to eating with their changed digestive system, though this can take many months. Some patients develop dumping syndrome, a condition where food moves too quickly from the stomach into the small intestine, causing nausea, cramping, diarrhea, and feeling faint after eating. Eating smaller meals, avoiding very sweet foods, and lying down for a short time after eating can help manage dumping syndrome symptoms. With time and dietary adjustments, many people find a new normal in their eating patterns, though they typically need to eat differently than before their diagnosis^[25].

Follow-up Care and Monitoring

After completing initial treatment for gastroesophageal cancer, regular follow-up appointments are crucial for detecting any signs that the cancer might be returning and for managing long-term effects of treatment. During the first two years after treatment, when the risk of recurrence is highest, doctors typically recommend appointments every three to six months. These visits include a physical examination, discussion of any new symptoms, and often imaging tests such as CT scans or endoscopy to look inside the esophagus and stomach. Blood tests may also be performed to check overall health and nutritional status^[22].

Patients should report any worrying symptoms immediately rather than waiting for a scheduled appointment. Warning signs that might indicate cancer recurrence include new or worsening difficulty swallowing, unintended weight loss, persistent pain in the chest or back, vomiting blood, or black, tar-like stools. While these symptoms can have causes other than cancer recurrence, they require prompt medical evaluation^[22].

Long-term survivors of gastroesophageal cancer often need ongoing support for nutritional issues, as the changes to their digestive system are permanent. Some people require vitamin and mineral supplements, particularly vitamin B12, iron, calcium, and vitamin D, which may not be absorbed properly after stomach surgery. Regular monitoring of nutritional status helps doctors identify and correct deficiencies before they cause serious problems^[25].